Date: 2025/05/05 - 23:00
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 drug resolved liver inflammation in nearly two-thirds of participants, twice the rate seen with placebo.
Date: 2025/04/29 - 23:00
"Ozempic feet" and "Ozempic mouth" are the latest reported cosmetic side effects from GLP-1 medications used for weight loss. Experts say wrinkles and sagging skin can result from rapid weight loss due to loss of fat and muscle mass in certain areas of the body.
Date: 2025/04/04 - 22:32
Legendary actor Val Kilmer, best known for his role as Iceman in "Top Gun," has died of pneumonia at 65. Experts say Kilmer's prior treatment for throat cancer and his age may have been contributing factors. Older adults can protect their health by getting vaccinated against pneumonia.
Date: 2025/04/02 - 23:32
The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medications. Here, two people who've relied on compounded GLP-1 drugs share their stories.
Date: 2025/04/02 - 23:00
The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medications. Here, two people who've relied on compounded GLP-1 drugs share their stories.
Date: 2025/03/26 - 03:00
A new study found that chewing gum releases hundreds to thousands of microplastics into saliva. Both synthetic and natural gums were found to contain microplastics, the health effects of which are not yet fully understood.
Date: 2025/03/20 - 00:00
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now that the GLP-1 drug shortage has ended. People who rely on compounded GLP-1s say they may not be able to afford brand-name versions, which are often not covered by insurance.
Date: 2025/03/17 - 15:01
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label treatment, according to a new study funded by pharmaceutical company Eli Lilly.